Epsilogen Acquires TigaTx to Lead Pan-Isotype Cancer Antibodies
April 7, 2025
The acquisition combines IgA antibody assets and expertise of Boston-based TigaTx with Epsilogen’s assets and expertise in IgE to create the world’s leading pan-isotype cancer